Medable Brings Digital Trial Platform to Google Cloud Marketplace
New partnership leverages Google’s infrastructure and artificial intelligence capabilities.
Medable has announced a collaboration with Google Cloud to bring its Digital and Decentralized Clinical Trial Platform to Google Cloud Marketplace. Customers of Medable will benefit from Google’s infrastructure and artificial intelligence capabilities with accelerated operations in clinical trial design, deployment, and management.1
In a press release, Michelle Longmire, MD co-founder and CEO of Medable said, “This alliance provides life sciences companies with Medable’s cutting-edge clinical development technology powered by Google Cloud through Google Cloud Marketplace. The collaboration will enable scaled and seamless adoption of Medable solutions by Google Cloud users, providing life sciences companies with platform capabilities proven to improve patient access to trials and accelerate critical development efforts, globally.”
In addition to its Digital and Decentralized Clinical Trial Platform, Medable’s newly launched Studio will integrate seamlessly with Google Cloud Marketplace.
“Bringing Medable’s platform to Google Cloud Marketplace will help customers quickly deploy, manage, and expand their use of the AI-driven clinical trial platform on Google Cloud's trusted, global infrastructure," Dai Vu, managing director, marketplace & ISV GTM programs at Google Cloud, said in the press release.
Medable Studio was introduced earlier in August. The application offers customers an all-in-one solution for electronic clinical outcome assessment (eCOA) management. It has capabilities in configuration, translation, and validation throughout the eCOA launch process. Customers of Studio can choose between self-service, full-service, or a combination of options.2
“Medable Studio upends the traditional study build/test/launch process by streamlining it using intelligence and automation,” Tim Smith, chief technology officer and co-founder, Medable, said in an earlier press release. “With Medable Studio, timelines shift from weeks and months to just days. Customers described Studio as a quantum leap in speed, scale, and quality, and it empowers sponsors with complete visibility and control over the entire process.”
Functions of Studio include:
- Point-and-Click Builder: Creates assessments, instruments, and diaries with features like no-code formatting, live preview, branching rules, and globalization support for translations.
- Visual Schedule of Assessments Builder: Adds assessments and instruments to a study schedule and configures standard visits, workflows and notifications, as well as unscheduled and remote visits.
- Translation Workbench: Manages translations and streamlines the sending and import processes.
- Content Library: Stores assessments, instruments, translations, and locales in one system.
In the press release, Longmire added, “This is just the start to transforming how evidence is generated. Medable Studio is where trial teams go to create. It allows for greater scalability, efficiency gains, and better, protocol-fit science. Studio will set new benchmarks for trial execution and ultimately advance our mission to enable effective therapies to reach patients faster by reducing trial start-up timelines and cost.”
References
1. Medable Joins Forces with Google Cloud to Deliver Digital Clinical Trials Technology on Google Cloud Marketplace. News release. Medable. October 30, 2024. Accessed November 1, 2024. https://www.businesswire.com/news/home/20241030519844/en/Medable-Joins-Forces-with-Google-Cloud-to-Deliver-Digital-Clinical-Trials-Technology-on-Google-Cloud-Marketplace
2. New Medable Studio Empowers Sponsors to Launch eCOA Solutions Into Clinical Trials With Unparalleled Control and Efficiency. News release. Medable. August 14, 2024. Accessed November 1, 2024. https://www.businesswire.com/news/home/20240814443065/en/New-Medable-Studio-Empowers-Sponsors-to-Launch-eCOA-Solutions-Into-Clinical-Trials-With-Unparalleled-Control-and-Efficiency
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
